Effect of silymarin on biliary bile salt secretion in the rat. 2000

F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
Instituto de Fisiología Experimental, Facultad de Ciencias Bioquímicas y Farmacéuticas, CONICET - U.N.R., Suipacha 570, 2000, Rosario, Argentina.

The effect of the hepatoprotector silymarin on bile secretion, with particular regard to bile salt secretion, was studied in Wistar rats. Silymarin (25, 50, 100, and 150 mg/kg/day, i.p., for 5 days) induced a dose-dependent increase in bile flow and bile salt secretion, the maximal effect being reached at a dose of 100 mg/kg/day (+17 and +49%, for bile flow and bile salt output, respectively; P < 0.05). Assessment of bile salt composition in bile revealed that stimulation of the bile salt secretion was accounted for mainly by an increase in the biliary secretion of beta-muricholate and, to a lesser extent, of alpha-muricholate, chenodeoxycholate, ursodeoxycholate, and deoxycholate. The maximum secretory rate (T(m)) of bile salts, as assessed by infusing the non-hepatotoxic bile salt tauroursodeoxycholate i.v. at stepwise-increasing rates, was not influenced by silymarin. The flavonolignan also increased the endogenous bile salt pool size (+53%, P < 0.05) and biliary bile acid excretion after bile acid pool depletion (+54%, P < 0.05), a measure of de novo bile salt synthesis. These results suggest that silymarin increases the biliary excretion and the endogenous pool of bile salts by stimulating the synthesis, among others, of hepatoprotective bile salts, such as beta-muricholate and ursodeoxycholate.

UI MeSH Term Description Entries
D008297 Male Males
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile
D001659 Biliary Tract The BILE DUCTS and the GALLBLADDER. Biliary System,Biliary Tree,System, Biliary,Tract, Biliary,Tree, Biliary
D012838 Silymarin A mixture of flavonoids extracted from seeds of the MILK THISTLE, Silybum marianum. It consists primarily of silybin and its isomers, silicristin and silidianin. Silymarin displays antioxidant and membrane stabilizing activity. It protects various tissues and organs against chemical injury, and shows potential as an antihepatoxic agent. Carsil,Karsil,Legalon,Silimarin
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D020011 Protective Agents Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. Protective Agent,Protective Drug,Protective Drugs,Agent, Protective,Agents, Protective,Drug, Protective,Drugs, Protective

Related Publications

F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
November 1994, Digestive diseases and sciences,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
April 1989, Gastroenterology,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
July 1971, Surgery,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
February 2000, Liver,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
July 1962, The American journal of physiology,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
December 1978, European journal of clinical investigation,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
January 1988, Annals of clinical research,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
August 1990, The Journal of nutritional biochemistry,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
August 1978, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie,
F A Crocenzi, and J M Pellegrino, and E J Sánchez Pozzi, and A D Mottino, and E A Garay, and M G Roma
January 1992, Journal of hepatology,
Copied contents to your clipboard!